key: cord-0802574-0x2jszj1
authors: O’Donghaile, Diarmaid; Jenkins, P. Vincent; McGrath, Rachel T.; Preston, Lisa; Field, Stephen P.; Ward, Soracha E.; O’Sullivan, Jamie M.; O’Donnell, James S.
title: Expresser phenotype determines ABO(H) blood group antigen loading on platelets and von Willebrand factor
date: 2020-10-27
journal: Sci Rep
DOI: 10.1038/s41598-020-75462-2
sha: 25aad2c53bf5cda5bc8a8fb1c660beccc4483f2c
doc_id: 802574
cord_uid: 0x2jszj1

ABO blood group is associated with cardiovascular disease, with significantly lower risk in blood group O individuals. ABO(H) blood group determinants are expressed on different glycoproteins on platelet surfaces. In addition, ABO(H) structures are also present on VWF glycans. These ABO(H) carbohydrates influence both platelet and VWF function. Previous studies have reported that approximately 5–10% of normal blood donors express abnormally high or low levels of A or B blood group antigens on their platelet surfaces (high expresser phenotype, HXP or low expresser phenotype, LXP respectively). In this study, the biological effects of the ABO Expresser phenotype were investigated. ABO(H) expression on platelets and plasma VWF was studied in a series of 541 healthy blood donors. Overall, 5.6% of our study cohort were classified as HXP, whilst 4.4% satisfied criteria for LXP. We demonstrate that genotype at the ABO blood group locus plays a critical role in modulating the platelet HXP phenotype. In particular, A(1)A(1) genotype is a major determinant of ABO high-expresser trait. Our data further show that ABH loading on VWF is also affected by ABO expresser phenotype. Consequently, A antigen expression on VWF was significantly elevated in HXP individuals and moderately reduced in LXP subjects (P < 0.05). Collectively, these findings suggest that ABO expresser phenotype influences primary hemostasis though several different pathways. Further studies will be required to define whether inter-individual variations in ABO(H) expression on platelets and/or VWF (particularly HXP and LXP) impact upon risk for cardiovascular disease.

The ABO blood group system was first recognized by Landsteiner in 1900. Subsequent studies have shown that the ABO gene locus is located on chromosome 9 and elucidated the genetic basis underlying different ABO groups 1 . In blood group A, B or AB individuals, alleles at the ABO locus encode glycosyltransferase enzymes which catalyze addition of either N-acetylgalactosamine (blood group A) or galactose (blood group B) as capping sugar moieties onto preformed glycan structures 1, 2 . In blood group O individuals, the ABO locus does not encode a functional transferase enzyme. Consequently, these subjects express unmodified H antigen precursor structures. The presence of ABO(H) blood group antigens on the surface of red blood cells, and their clinical relevance in blood transfusion, is well recognized 3 . Importantly however, ABO(H) antigens are also expressed on other human cells types including endothelial cells (EC) and epithelium 4 . In addition, ABO(H) determinants are expressed on platelets, where they have been identified on a variety of different glycoproteins known to play important roles in hemostasis (including GPIb, GpV, GpIIb/IIIa and PECAM-1) 5 . Recent studies have demonstrated that these ABO(H) glycans on the platelet membrane surface significantly influence normal platelet function [5] [6] [7] .

In addition to their cellular expression, covalently-linked ABO(H) structures have also been described on a number of plasma glycoproteins, including von Willebrand factor (VWF), factor VIII (FVIII) and α 2macroglobulin 8 . ABO(H) expression on VWF has been characterized in detail 9 . Mass spectrometry (MS) studies have confirmed that ABO(H) determinants are present on both the N-and O-linked glycans of human www.nature.com/scientificreports/ plasma-derived VWF [10] [11] [12] . Interestingly, although H antigen is expressed on platelet-derived VWF, there is no A or B antigen expression 13, 14 . ABO(H) expression on VWF is important because it has been shown to regulate multiple aspects of VWF biology 15, 16 . First, ABO affects plasma levels of the VWF-FVIII complex, with significantly lower levels in blood group O compared to non-O subjects 17 . This difference is likely attributable to enhanced VWF clearance in group O individuals 18, 19 , ABO expression on VWF modulates susceptibility to proteolysis by ADAMTS13, with significantly enhanced cleavage in blood group O subjects 20, 21 . Third, accumulating recent evidence suggests that ABO antigens on VWF also influence its functional ability to interact with platelet GPIb 6, 22 . Given the biological importance of ABO(H) expression in regulating platelet and VWF function, it is interesting that marked inter-individual variability in quantitative ABH antigen expression has been reported in healthy individuals [23] [24] [25] . Furthermore, several studies have described a so called ABO 'High Expresser Phenotype' (HXP), wherein some normal donors express unexpectedly high levels of A or B blood group determinants on their platelets 23, 24, 26 . Although first described in a cohort of Japanese blood donors 26 , HXP has subsequently been identified in other different ethnic groups with a reported population prevalence of approximately 5% 23, 24, 27 . This high expresser trait has been observed in subjects with each of the non-O blood groups (A, B and AB respectively), and has been shown to constitute a stable characteristic over time in affected subjects 23, 24 . Despite the prevalence and potential translational importance of ABO HXP, the molecular mechanism(s) responsible for mediating increased platelet A or B antigen expression in these individuals remains poorly defined. However familial clustering of HXP has been reported, suggesting that inherited factors contribute to its etiology 23 .

In this study, we investigated the relationship between ABO genotype, platelet expresser phenotype, and ABO(H) loading on plasma VWF. Our findings demonstrate that expresser phenotype effect is not confined to ABH expression on platelets, but rather also regulates quantitative ABH loading on plasma VWF. Given the importance of ABO in modulating the biological functions of VWF, these findings are not only of scientific interest but also of direct clinical relevance.

Patient enrolment and ABO typing. Blood samples were collected from healthy adult donors attending the Irish Blood Transfusion Service (IBTS). All donors gave informed consent. The St James' Hospital Research Ethics Committee has approved the study. In total, samples were collected from 231 group A and 310 group O donors over a one year period. All methods were carried out in accordance with relevant guidelines and regulations. Group A donor sub-grouping was determined by standard red cell serology (i.e. donor red cells that failed to agglutinate when incubated with anti-A 1 were considered A 2 ) 24 . For all blood group A subjects, ABO genotype was also determined. In brief, genomic DNA was extracted from whole blood using Gentra-Qiagen Autopure (Alameda, CA) as per the manufacturer's instructions. PCR was then performed to amplify exons 6 and 7 of the ABO gene using oligonucleotide primers as previously described 28 . Primers ABO-1 and ABO-2 in conjunction with the restriction enzyme KpnI were used to differentiate O 1 alleles from A 1 and A 2 alleles. Primers ABO-3 and ABO-4 in conjunction with the restriction enzyme PvuII were used to differentiate A 2 alleles from A 1 and O 1 alleles.

Platelet-rich plasma was prepared by centrifugation of whole blood. Platelet count was then measured using a Cell-Dyn 3200 analyser (Abbott laboratories, IS). To assess A antigen expression levels, 10 6 platelets were incubated with Phycoerythrin (PE)-labeled anti-human CD41a (BD Biosciences Pharmingen; San Diego, CA) and Fluorescein (FITC)-labelled Helix pomatia (HPA, Anti-A) (Sigma-Aldrich; St. Louis, MO) for 30 min as previously described 28 . Samples were then analyzed using a BD FacsCanto II (BD Biosciences, San Jose, CA). Platelets staining dual-positive for both CD41a and anti-A were quantified, together with mean fluorescence intensity for CD41a and HPA expression. Data were quantified using FACSDiva software (BD Biosciences, San Jose, CA). In keeping with previous studies, HXP was defined as greater than 75% platelet A antigen positivity, and LXP defined as less than 15% platelet positivity 23, 24 . Similarly, FITC-labeled Ulex europaeus (UEA, anti-H) (Sigma-Aldrich; St. Louis, MO) was used to investigate H antigen expression on group O platelets. Finally, platelet α2-6 linked sialic acid expression was analyzed using FITClabeled Sambucus nigra agglutinin (SNA) (Vector Laboratories Inc: Burlingame, CA). For each glycan analysis, a parallel sample was analyzed using isotype control (FITC-labelled mouse IgG1κ isotype; BD Biosciences Pharmingen, San Jose, CA).

Plasma VWF antigen levels. Plasma VWF antigen (VWF:Ag) levels were measured by sandwich enzymelinked immunosorbent assay (ELISA) as previously described 29 . Briefly, 96-well ELISA plates (DAKO) were coated with rabbit polyclonal anti-human VWF antibodies (A082; Dako, Denmark) diluted in 0.05 M carbonate buffer (pH 9.6). After washing, the plates were incubated with the test samples or reference plasma. Following further washing, the plates were incubated with rabbit polyclonal anti-human VWF peroxidase conjugate, (P266; Dako, Denmark) for 1 h. VWF:Ag concentration was determined by measuring optical density at 492 nm. Dilutions of Reference plasma were used to construct standard curves for calibration. All ELISA samples were tested in duplicate. The intra-assay and inter-assay coefficients of variation were both less than 5% and the lower limit of VWF:Ag detection was 0.03 IU/mL. A antigen expression on plasma VWF. Group A (GalNAc α1 → 3 [Fuc α1 → 2] Galβ 1 → 4 GlcNAc β1 →) antigenic determinants on plasma were measured using a modified sandwich ELISA 28, 30 . In brief, ELISA plates were coated with rabbit anti-human VWF (Dako), washed and blocked using TBS containing 1% BSA. After further washings, plasma samples were added and incubated for 2 h at room temperature. Each plasma was tested in duplicate at three dilutions. The plates were washed and then incubated with murine anti-A mono-Scientific Reports | (2020) 10:18366 | https://doi.org/10.1038/s41598-020-75462-2 www.nature.com/scientificreports/ clonal antibody (Ortho Diagnostics) for 1 h. After a further three washes, the plates were incubated with goat anti-mouse IgM peroxidase conjugate (Sigma) for 1 h. After another TBS/Tween wash, peroxidase substrate solution was added. The reaction was stopped with 1 M H 2 SO 4 and the optical density measured at wavelength 492 nm. Pooled group A plasma was assayed to produce a standard curve for each ELISA. Using the standard curve, a value for A antigen on VWF expression was determined for each plasma sample. Plasma VWF:Ag concentration strongly influenced the amount of A antigen detected in each ELISA well. To determine the amount of A antigen expressed per unit VWF, the amount of A antigen detected was divided by the amount of VWF:Ag present in the ELISA well 28 . The pooled normal A plasma was assigned a value of 1U/ml for the amount of A antigen expressed per unit vWF.

Statistical analysis. Statistical analysis was performed using GraphPad Prism Version 5.0 (Graphpad Software, San Diego, CA) and statistical significance was assigned at a value of P < 0.05. Mann-Whitney U test was used to test differences in mean values.

High and low expresser phenotypes in normal Irish blood donors. 231 blood group A subjects were recruited from healthy donors. 182 (79%) of the donors were male and 49 (21%) were female. Red cell analysis confirmed that 180 (78%) donors were phenotypically A 1 , whilst the remaining 51 (22%) subjects were A 2 . For each donor enrolled, blood group A antigen expression on platelets was assessed by flow cytometry. In keeping with previous studies, significant heterogeneity in A antigen expression on platelets was observed even for a given individual subject (Fig. 1A) . In particular, a bimodal pattern of A antigen expression on group A platelets was observed in the majority of individuals studied. Previous studies have applied a diagnostic threshold of ≥ 75% platelets expressing A antigen in order to identify individuals with High Expressor Phenotype 23, 24 .

Using this criterion, 10 (5.6%) of our study cohort were classified as HXP. In keeping with previous findings, we observed two distinct subgroups within our HXP cohort. In 8 HXP subjects, the platelet histogram was similar in shape to that of normal A 1 platelets, but shifted to the right toward higher values (type I HXP) (Fig. 1B) . In contrast, 2 HXP subjects had platelet histograms consisting of a single sharp peak (type II HXP) (Fig. 1C ). In keeping with previous studies, repeat sampling confirmed that HXP was a consistent finding in affected individuals over time 23, 24 . Minimal platelet A antigen expression was seen in blood group A 2 individuals (Fig. 1D ). Finally, 8 A 1 donors demonstrated significantly reduced A antigen expression (≤ 15% platelets expressing A antigen) and were classified as Low Expresser Phenotype (LXP) (Fig. 1E) . Collectively, these data demonstrate that significant intra-and inter-individual heterogeneity in platelet A antigen expression is present amongst healthy subjects. Moreover, a significant proportion of normal donors demonstrate abnormally ABO High or Low Expresser Phenotypes.

ABO genotype and expresser phenotype. In blood group A 2 individuals, a deletion in the ABO gene results in a frame-shift, which significantly reduces the activity of the A transferase enzyme compared to A 1 subjects 31 . Consistent with this concept, platelet A antigen expression was significantly increased in group A 1 compared to A 2 healthy donors and all of the subjects classified as HXP were A 1 ( Fig. 2A) . Interestingly however, the amount of A antigen expressed on platelets varied widely between the different individuals ( Fig. 2A) Fig. 2B ). Furthermore, 7 of the 10 individuals classified as HXP were also found to have genotype A 1 A 1 . Surprisingly, given the limited A transferase activity associated with the A 2 allele, two of the other HXP donors genotyped as A 1 A 2 (Fig. 2B) . The prevalence of HXP amongst A 1 A 1 subjects was significantly increased compared to the total A donor population (28% versus 4.3%; P < 0.05). In contrast, the prevalence of HXP was markedly reduced in heterozygous A 1 O 1 donors (0.7%). All the LXP subjects identified in our cohort had an A 1 O 1 genotype. Together, these data clearly demonstrate a major role for ABO gentoype in modulating quantitative A antigen expression on platelets in normal subjects and further suggest that genotype is an important factor in HXP etiology.

on human erythrocyte surfaces influences α2-6 linked sialic acid presentation by stabilizing sialylated glycan clusters 32 . Consequently, Sambucus nigra agglutinin (SNA) lectin binding to erythrocytes was shown to differ significantly between ABO blood groups (A > O > B) 32 . Given these data, we investigated whether there was a relationship between ABO blood group and sialic acid expression on platelets. Similar to A antigen expression, significant inter-individual variability in platelet sialylation was observed (Fig. 3A) . However, unlike the bimodal pattern observed for platelet A antigen expression, SNA platelet-binding demonstrated a single positive unimodal distribution (Fig. 3B) . The difference in α2-6 linked sialylation compared to A antigen expression on platelets is interesting, since both are characterized by single terminal sugar moieties on the end of complex glycan chains. Critically however, unlike in erythrocytes, no significant relationship between ABO group and α2-6 linked sialylation on platelets was seen (Fig. 3C) . Furthermore, we observed no correlation between neither quantitative A or H antigen expression and platelet SNA binding (data not shown). www.nature.com/scientificreports/ Plasma VWF in high and low expressor phenotypes. Based upon our ABO genotype and H antigen expression data, we hypothesized that increased glycosyltransferase expression may be important in platelet HXP etiology. To further investigate this hypothesis, we next studied whether ABO genotype and expresser phenotype had any effect on quantitative loading of A antigen on plasma VWF (AVWF). Using a previously optimized modified sandwich Elisa 28 , AVWF was measured for each individual in our group A cohort. Although marked inter-individual variability in AWF was observed, a significant effect of ABO genotype was also seen (Fig. 4A) . Consistent with our platelet data, AVWF was significantly increased in homozygous A 1 A 1 individuals compared to heterozygous A 1 O 1 subjects and minimal A loading on plasma VWF was observed in A 2 subjects (Fig. 4A) . In addition, a significant relationship between platelet ABO expresser phenotype and quantitative AVWF expression was also observed, with AVWF levels significantly increased in platelet HXP subjects compared to group A individuals (P < 0.05; Fig. 4B ). Finally, a dosage effect of platelet expresser phenotype on AVWF was seen, with significantly increased in platelet HXP subjects compared to those classified with a normal expresser phenotype (P < 0.05; Fig. 4C ). Conversely, AVWF was markedly reduced in in platelet LXP compared to HXP individuals (P = 0.02; Fig. 4C ). Consistent with previous studies, plasma VWF:Ag levels were significantly higher in blood group A 1 subjects (genotypes A 1 A 1 or A 1 O 1 ) compared to either A 2 or group O respectively (Fig. 5A) . Although A antigen loading on VWF was significantly higher in HXP individuals, no effect on plasma VWF:Ag levels was observed (Fig. 5B) . www.nature.com/scientificreports/ www.nature.com/scientificreports/ fact that our population were almost all Caucasian, it is interesting that these frequencies are remarkably similar to those reported in similar studies performed in other ethnic groups 23, 26, 27 .

With respect to the relationship between ABO and cardiovascular risk, it is important to emphasize that ABO(H) blood group determinants are expressed on a variety of different glycoproteins and glycolipids on the platelet surface 5 . It remains unclear whether the HXP/LXP effects apply equally to ABO(H) loading on each of these different platelet glycoproteins. Importantly however, previous studies reported that HXP specifically influenced quantitative ABO(H) expression on the platelet GpIb 23 . This observation is interesting because ABO directly influences GpIb functional activity 6 . Using video microscopy, Dunne et al. demonstrated that the ability of group O platelets to interact with immobilized VWF was significantly reduced compared to non-O platelets 6 . Consequently, under arterial shear conditions, type O platelets travelled further and moved at faster translocation velocities before they were able to form stable interactions with immobilized VWF. Subsequent analyses Figure 4 . The relationship between ABO genotypes, ABO expresser phenotypes and the amount of A antigen loading on plasma VWF. To determine whether expresser phenotype influences ABO loading on plasma VWF, the amount A expressed per unit VWF (AVWF) was quantified in each blood group A donor using a modified sandwich ELISA. All experiments were performed in triplicate, and pooled normal A plasma was assayed to produce a standard curve. (A) A antigen expression on plasma VWF was significantly elevated in homozygous A 1 A 1 donors compared to A 1 A 2 or A 1 O 1 individuals. In keeping with previous reports, minimal A antigen expression on plasma VWF was observed in group A 2 subjects. (B) A antigen expression on plasma VWF was significantly increased in HXP subjects compared to normal A 1 controls (*P < 0.05). (C) A antigenic loading on VWF was significantly higher in HXP individuals compared to those with a normal-(NXP) or low-(LXP) expresser traits (*P < 0.05; *** P < 0.001). 38, 39 .

In addition to influencing platelet function, ABO(H) blood group antigens are also expressed on VWF and FVIII in normal human plasma 35 . Importantly in the context of the association between ABO group and vascular disease, ABH determinants expressed on VWF glycans have been shown to influence VWF functional activity; VWF susceptibility to proteolysis and VWF clearance 35 . Thus, in keeping with their reduced thrombotic risk, plasma levels of the VWF-FVIII complex are significantly lower in blood group O compared to non-O individuals. Our findings demonstrate that similar to platelets, ABH expression on plasma VWF also varies widely between normal subjects. For the first time, we further demonstrate that ABH loading on VWF is also affected by ABO expresser phenotype. Consequently, although the number of subjects was limited, A antigen expression on VWF was significantly elevated in HXP individuals and moderately reduced in LXP subjects. Current evidence suggests that addition of ABO(H) determinants occurs during post-translational modification within EC rather than in the peripheral circulation 15, 40, 41 . Consequently, our findings suggest that the molecular mechanisms underlying HXP and LXP are likely shared across a number of different cell types. Despite the significant effect of www.nature.com/scientificreports/ high expresser-trait in regulating ABO expression on plasma VWF, we observed no significant effect on plasma VWF:Ag levels. This may be attributable to the small number of HXP individuals in our cohort. Alternatively, it is possible that the relationship between ABO blood group and plasma VWF clearance rate is not regulated via ABH determinants expressed on VWF glycans. To investigate mechanisms that may contribute to expresser-traits, we performed ABO genotyping for subjects in our cohort. A antigenic loading on both platelets and VWF was significantly increased in homozygous A 1 A 1 compared to heterozygous A 1 O 1 individuals. In addition, minimal A antigen expression was present on platelets or VWF in A 2 subjects. Importantly, 7/10 of the individuals with ABO HXP had an A 1 A 1 genotype. However, the majority of individuals with an A 1 A 1 genotype did not have evidence of abnormally elevated A antigen expression on either platelets or VWF, and were not classified as HXP. Moreover, 3 HXP subjects were shown to have genotypes A 1 A 2 or A 1 O 1 respectively. Collectively, these data highlight that ABO genotype is an important factor in determining HXP. Given the known dosage effect of the ABO gene 28 . we postulate that increased glycosyltransferase expression represents at least in part the likely causal mechanism 23 . This hypothesis is supported by a previous study that reported elevated glycosyltransferase enzymes in the serum of HXP subjects. Nevertheless, since not all A 1 A 1 individuals exhibit elevated platelet A antigen expression, clearly additional and as yet unrecognized mechanisms must also be involved in contributing to ABO HXP pathogenesis.

In the majority of A 1 donors, flow cytometry studies showed a bimodal pattern of A antigen expression on platelets. Thus, in the same individual at the same time point, some platelets demonstrated strong A antigen expression whilst other platelets had low A antigen. Although these findings are consistent with several previous studies 23, 24 , the underlying mechanism remains unknown. To gain further insight into factors that might modulate ABO(H) loading on platelets and VWF, we measured α2-6 linked sialic acid expression on platelets. Similar to ABO(H) determinants, α2-6 linked sialic acid is expressed as a terminal capping sugar moiety at the end of glycan antennae 42 . Although recent studies reported a relationship between ABO blood group and terminal sialylation on human red cells 32 , we found no evidence that α2-6 linked sialylation influences quantitative ABO(H) expression on either platelets or VWF respectively.

In conclusion, our findings highlight the fact that ABO expresser traits significantly influence quantitative ABO(H) expression on both platelets and plasma-derived VWF. This concept is important when considering potential biological pathways that may explain emerging GWAS data identifying ABO as a disease-associated locus. Additional studies will be required to define whether HXP and LXP also influence ABH expression in other tissues. In addition, further research will also be necessary to elucidate whether inter-individual variations in ABO(H) expression on platelets and/or VWF (particularly HXP and LXP) impact upon risk for cardiovascular disease (e.g. bleeding, thrombosis, TTP) 8, 43 , or indeed susceptibility to specific types of sepsis. www.nature.com/scientificreports/

Molecular genetics of ABO

The blood group-specific human glycosyltransferases

The ABO blood group system revisited: a review and update

The histo-blood group ABO system and tissue transplantation

ABO blood group as a model for platelet glycan modification in arterial thrombosis

Blood group alters platelet binding kinetics to von Willebrand factor and consequently platelet function

Influence of ABO Locus on PFA-100 Collagen-ADP Closure Time Is Not Totally Dependent on the Von Willebrand Factor. Results of a GWAS on GAIT-2 Project Phenotypes

The relationship between ABO blood group, von Willebrand factor and primary hemostasis

The relationship between ABO histo-blood group, factor VIII and von Willebrand factor

Mapping the N-glycome of human von Willebrand factor

The plasma von Willebrand factor O-glycome comprises a surprising variety of structures including ABH antigens and disialosyl motifs

Site-specific analysis of von Willebrand factor O-glycosylation

Platelet von Willebrand factor-structure, function and biological importance

Altered glycosylation of platelet-derived von Willebrand factor confers resistance to ADAMTS13 proteolysis

Elucidating the role of carbohydrate determinants in regulating hemostasis: insights and opportunities

New developments in von Willebrand disease

The effect of ABO blood group on the diagnosis of von Willebrand disease

A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor

Willebrand factor clearance-biological mechanisms and clinical significance

An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13

Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis

Role of A and B blood group antigens in the expression of adhesive activity of von Willebrand factor

Blood group A and B antigens are strongly expressed on platelets of some individuals

Determinants of ABH expression on human blood platelets

Relationship between ABO genotype and A antigen expression on platelets

Study on the expression of ABH antigens on platelets

Prevalence, serologic and genetic studies of high expressers of the blood group A antigen on platelets*

Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels

Genotype at the secretor blood group locus is a determinant of plasma von Willebrand factor level

Increased galactose expression and enhanced clearance in patients with low von Willebrand factor

Molecular genetic basis of the histo-blood group ABO system

ABO blood group glycans modulate sialic acid recognition on erythrocytes

ABO blood group phenotypes and Plasmodium falciparum malaria: unlocking a pivotal mechanism

Association between ABO blood groups and risk of SARS-CoV-2 pneumonia

ABO blood group determines plasma von Willebrand factor levels: a biologic function after all?

Emerging roles for hemostatic dysfunction in malaria pathogenesis

ABO(H) blood groups and vascular disease: a systematic review and meta-analysis

Significant gynecological bleeding in women with low von Willebrand factor levels

Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels

Carbohydrates of the cell surface: molecular aspects of glycosyltransferases and their genes

Human umbilical vein endothelial cells differ from other endothelial cells in failing to express ABO blood group antigens

Willebrand factor sialylation-A critical regulator of biological function

Low VWF: insights into pathogenesis, diagnosis, and clinical management

This work was supported by funds from the NIH for the Zimmerman Program (HL081588); a Science Foundation Ireland Principal Investigator Award (11/PI/1066); a Health Research Board Investigator Lead Project Award (ILP-POR-2017-008) and a National Children's Research Centre Project Award (C/18/1). The study was also funded by the Irish Blood Transfusion Service. PVJ is supported by Health and Care Research Wales CRT award 2016-05.

Correspondence and requests for materials should be addressed to J.S.O.Reprints and permissions information is available at www.nature.com/reprints.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.